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The immune system protects the body against infections and cancer. A type of lymphocyte 
called “helper T cell” plays a vital role in coordinating immune responses. Helper T cells are 
arguably the most important type of immune cell as they are required for almost all adaptive 
immune functions. T cells play a vital role in the adaptive immune system, however, very little is 
known about their metabolic pathways. When presented with an antigen, helper T cells proliferate, 
differentiate and produce cytokines. The activation of helper T cells is metabolically demanding. 
T cells require large amounts of glucose from their environment as they proliferate. Glycolytic by-
products support rapid cell division through the building of biomass. Systematically, excess 
glucose is stored in the liver in the form of glycogen, but there is growing evidence that glycogen 
is found in non-hepatic cells as well. With an increase in glucose uptake in helper T cells, surplus 
must be stored for later use. Currently, there is very little knowledge on the role of glycogen 
dynamics in helper T cells. I hypothesized that glycogen is important in helper T cell proliferation 
and cytokine production. I demonstrated that isolated human helper T cells accumulated glycogen 
upon activation. Activated T cells accumulated a greater amount of glycogen as compared to non-
activated cells (p<0.0001). The enzyme α-amylase, added as a control, digested glycogen and 
reduced the glycogen signal. Inhibition of glycogen breakdown significantly attenuated 
proliferation and had a trend to decrease pro-inflammatory cytokine IL-17A production in 
activated peripheral blood mononuclear cells. This is among the first accounts of glycogen 
dynamics in helper T cells. It is important to study helper T cells because they are implicated in 
autoimmune diseases and immune deficiencies. This newfound understanding on how helper T 
cells manage their metabolic needs during an immune response could aid in the development of 
immunomodulatory treatments. 
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CHAPTER 1 - INTRODUCTION 
 
In this thesis, glycogen metabolism and glycogen dynamics was explored in activated 
human helper T cells. In particular, my goal was to demonstrate the presence of glycogen during 
activation of the immune system. Additionally, I sought to test the importance of glycogen in 
effector function of T cells. This is amongst the first times that glycogen was observed in helper T 
cells. The glycogen molecule has commonly been viewed as a characteristic polymer of hepatic 
and muscle cells, used to systemically provide the body with glucose in times of low energy 
(Alberts et al., 2009). We now know that glycogen storage occurs in a variety of non-hepatic cells 
such as immune cells (Arrizabalaga et al., 2012; Hedeskov, 1968; Ma et al., 2018; Quaglino et al., 
1962; Sadiku et al., 2017; Tabatabaei Shafiei et al., 2014; Thwe et al., 2017).  Our group 
contributed to this discovery by demonstrating that peripheral blood mononuclear immune cells 
(PBMCs) increased glycogen storage when subjected to specific types of T cell activation in vitro 
(Tabatabaei Shafiei, 2016). Here, I delved deeper into the helper T cell subset to test the hypotheses 
that they increased their glycogen storage when activated and that helper T cells require glycogen 
to proliferate properly in vitro. This research provided insight on a metabolic change occurring 
within T lymphocytes that were undergoing activation in vitro. 
 
1.1 Infectious disease and the cell types of the immune system 
The immune system eradicates pathogens from our body without attacking healthy tissues. 
Humans are made up of approximately 1013 human cells and 1014 bacterial, fungal and protozoan 
organisms at all times (Alberts et al., 2002). While microbes outnumber human cells 10 to 1, these 
organisms live symbiotically as part of the microbiome and gut flora. Humans, however, 
frequently experience pathogenic microorganisms that could cause illness. The immune system is 
composed of many types of cells that work together to engulf, overwhelm and eradicate infection 
throughout the body. A culmination of molecular pathways mediates immune cell responses. Any 
slight alterations in any of these pathways could cause an inability to perform their proper immune 
function (McKinney and Smith, 2018; Snapper et al.,  1996). If our immune cells lose the ability 
to react to an infectious disease or gain the ability to recognize self-tissue as foreign, this results 
in illness or autoimmune disease, respectively (McKinney and Smith, 2018).   
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1.2 Adaptive Immune Response and T cell development 
The adaptive immune system is comprised of B cells and T cells. T cells will be the focus 
of this thesis. Adaptive immune cells respond to a small fraction of the foreign pathogen called an 
antigen. This antigen is displayed through a transmembrane receptor called the major 
histocompatibility complex (MHC)-II or MHC-I. Both MHC types are located on the surface of 
professional antigen-presenting cells (APC), while all nucleated cells, including infected cells, 
express MHC-I. APCs present the antigen/MHC complex to helper T cells (identified by CD4 cell 
surface protein) through MHC-II. Cytotoxic T cells (identified by CD8 cell surface protein) 
recognize an antigen through the MHC-I receptor on the surface of antigen presenting cells and 
infected, cancerous or dying somatic cells. Before becoming either a cytotoxic T cell or helper T 
cell, the progenitor T cells from the bone marrow undergo a rigorous positive selection process. 
Progenitor cells travel from the bone marrow and enter the thymus as double negative for both 
CD4 and CD8, where they become double positive for CD4 and CD8, and leave as single positive 
for either one. Most autoreactive T cells are naturally killed in the thymus which provides a degree 
of immunological tolerance, this is called negative selection. When the cells leave the thymus, they 
are naïve T cells (either CD8 cytotoxic or CD4 helper). A naïve T cell is defined as a cell that has 
successfully undergone positive and negative selection in the thymus and is single positive for 
either CD4 or CD8. The naïve T cell has not encountered a foreign antigen and remains at rest. 
Naïve T cells that leave the thymus travel through the blood and through the lymphatic system to 
secondary lymphoid tissue (lymph nodes or the spleen). Positive and negative selection in the 
thymus are important to maintain a healthy, balanced immune system that can sense and attack 
foreign antigens while ignoring self-tissue (von Boehmer, 1992).  
Helper T cells can cause disease in the body. Autoimmune disease occurs when a helper T 
cell’s cognate antigen is located on self-tissue. An example of self-recognition is when helper T 
cells recognize and elicit a response to myelin in multiple sclerosis. These T cells recruit other 
immune cells such as macrophages, B cells and microglia to degrade myelin as well as the 
accompanying oligodendrocytes in the central nervous system (Antel et al., 2018; Moore et al., 
2015; Salou et al., 2015). In patients with type-1 diabetes, autoreactive T cells identify pancreatic 
𝛽-cells as foreign and stimulate cell death. Ultimately 𝛽-cell degradation causes a reduction in 





Figure 1 – Antigen presenting cell and T cell interaction. 
There are multiple signals that occur when an APC interacts with a T cell. The TCR recognizes 
the peptide displayed on the APC by MHC. The CD4 co-receptor binds to part of the MHC 
allowing for the stabilization of the TCR/MHC complex and stimulates downstream activity. 
Intracellularly, tyrosine kinases on the tail end of CD4 phosphorylates immunoreceptor tyrosine 
activation motif, which is found on the intracellular tail of CD3. CD28 interacts directly with the 
CD80 and CD86 causing a necessary co-stimulation that starts the cell’s metabolism and 
proliferation. CD28 is also required to increase glucose uptake through GLUT-1 and to reduce the 
threshold of the TCR.   
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Helper T cells can also cause injury within the body through cytotoxicity. Cytotoxic CD4+ helper 
T cells injure astrocytes through glial fibrillary acidic protein degradation. This reduces the ability 
for astrocytes to provide support for other brain cells, and prevents the astrocytes from properly 
repairing damaged areas (Stopnicki et al., 2019). These examples of autoreactive and cytotoxic 
helper T cells provide insight into the importance of research that continues to uncover the inner 
workings of the immune system and particularly helper T cells. This understanding allows 
scientists to better comprehend what changes are causing disease. 
 
1.3 Innate immunity and antigen presentation 
There are two main types of immune responses: the innate response and the adaptive 
response. The innate response is the front-line defense of the body; some molecular components 
are highly conserved among metazoans. These innate cells have highly conserved receptors, such 
as toll-like receptors, which allow innate cells to recognize and engulf pathogens (Aderem and 
Ulevitch, 2000; Roach et al., 2005). Professional APCs, such as dendritic cells (DCs) and 
macrophages, bridge the gap between the innate and adaptive immune response. APCs act mainly 
by internalizing antigens and then presenting them on their cell surface. Antigen presentation by 
APCs occurs through the MHC surface receptor. APCs, with MHC-antigen complex displayed on 
its surface, migrate to the lymphoid tissue to engage the adaptive immune cells by interacting with 
a specific matching T cell receptor (TCR). The MHC-antigen/TCR interaction provides the first 
activation signal for T cells (Figure 1). The MHC-II-antigen/TCR complex then requires additional 
interactions for T cell activation to proceed. For helper T cells, CD4 co-receptor binds to the MHC-
II molecule, aiding in recognition and enhancement of the activation signalling (Artyomov et al., 
2010). CD28 co-receptor, found on the helper T cell, binds to CD80 on the APC, providing the 
second stimulatory signal for T cell activation (Figure 1). CD28 interacts directly with CD80 and 
CD86, causing a necessary co-stimulation that starts the cell’s metabolism and proliferation.CD28 
stimulates downstream protein kinase C (PKC) activation. The resulting cascade causes production 
of interleukin 2 (IL-2) which facilitates T cell proliferation (Linsley et al., 1992). CD28 is also 
required to increase glucose uptake through GLUT-1 and to reduce the threshold of the TCR 
(Frauwirth et al.,  2002; Jacobs et al.,  2008). 
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1.4 T cell activation 
When a naïve helper T cell encounters MHC-II-antigen complex, it may become activated. 
Very few such encounters will result in activation. The naïve T cell must encounter a foreign 
antigen/MHC that matches its unique TCR. For naïve T cells, activation occurs through the 
interaction of the TCR complex and co-stimulatory transmembrane protein receptor CD28 
(Bluestone, 1995; Linsley et al.,  1992). The TCR variable region identifies the MHC-bound 
antigen, and the CD3 transmembrane molecules cause the intracellular cell signalling cascade. 
CD3 is present on all T cells and is a common extracellular identifier. Together, the TCR/MHC-
antigen complex and the CD28/CD80 interaction causes a cascade of reactions that result in the 
naïve T cell becoming an activated effector T cell (Smith-Garvin et al., 2009) When the TCR 
recognizes its cognate antigen the T cell starts to divide, making clones of itself. This process, 
called clonal expansion, increases the population of cells specific to this one antigen.  
T cell activation can be simulated in the laboratory in a variety of different ways (Figure 
2). In vitro, the TCR can be stimulated by adding anti-CD3 to the cell culture. A heterogenous 
population of immune cells derived from PBMCs can be activated in vitro by using the phorbol 
12-myristate 13-acetate (PMA). PBMCs are an isolated group of cells from whole blood that 
contain an array of immune cells, a large proportion of which are T lymphocytes. PMA bypasses 
the CD28 co-receptor by crossing the cell membrane and directly activating PKC. PMA has a 
similar structure to diacylglycerol, which allows it to activate PKC. Another method for T 
lymphocyte activation is through the addition of soluble (free floating) polyclonal antibodies that 
are specific for CD3 or CD28. It is thought that the soluble antibodies are presented to the T 
lymphocyte by monocytes in cell culture. Monocytes are a component of the PBMC suspension 
and can differentiate into macrophages or dendritic cells. Similar antibodies can also be fixed to a 
plastic surface in the form of micro-beads (dynabeads) which is most effective in activating helper 
T cells that are cultured without PBMC support. Measuring T cell activation usually involves 
measuring IL-2 and expression of CD69 on the cell surface (Kamphorst et al., 2017; Saparov et 
al., 1999). T cell proliferation is primarily induced by autocrine and paracrine IL-2 signalling. IL-
2 promotes the T cell through the cell cycle by upregulating cyclin proteins (Appleman et al., 2000; 
Modiano et al., 1994) whereas CD69 is the first notable receptor to be translocated to the 
membrane upon activation and is used as a marker for T lymphocyte activation (Cibrián and 
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Figure 2 – Activation of lymphocytes using different methods in vitro 
In the laboratory, T cell activation can be simulated with a variety of methods. A) PMA crosses 
the plasma membrane directly and interacts with PKC to cause a downstream activation cascade. 
B) Soluble anti-CD3 and anti-CD28 is presented to the lymphocytes by monocytes, therefore 
crosslinking the TCR. C) The dynabeads can be used without the need for APCs and are optimal 
for activating isolated T lymphocytes in vitro. 
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Proliferating T lymphocytes can be seen clustering together and can be monitored using 
microscopy techniques. An increase in cell area is an indicator of activation (Iritani et al., 2002; 
Rathmell et al., 2003). Helper T cell proliferation also can be monitored in vitro using dyes that 
decrease in intensity after each generation such as carboxyfluorescein succinimidyl ester (CFSE; 
described further in the materials and methods section). T cells that receive all of the necessary 
signals (CD3, CD28 and IL-2) can proliferate, and differentiate in order to more specifically target 
the threat. 
Mature helper T cells are necessary for both B cell activation, in the secondary lymphoid 
tissue, and propagation of the complement system (Crotty, 2015). Additionally, helper T cells 
release a slew of cytokines to recruit other immune cells, such as macrophages and neutrophils, to 
the site of infection (Franciszkiewicz et al., 2012). When the threat dissipates, helper T cells either 
die off or become memory T cells. Memory helper T cells can be identified by their exclusive 
expression of CD45RA. Memory cells can respond more rapidly the next time the same pathogen 
invades the body (Baaten et al., 2010). The helper T cell’s ability to cover a variety of functions 
makes them crucial to the immune system.  
 
1.5 The importance of CD28 co-stimulation 
Stimulation of helper T cells and the expansion of their antigen-specific population occurs 
through their interaction with professional APCs. In addition to the MHC/TCR interaction, CD80 
and CD86 on the APC binds to CD28 on the helper T cells. This stimulation decreases the threshold 
of the TCR activation (Esensten et al., 2016). Co-stimulation is critical for controlled activation 
and increased proliferation of T lymphocytes (Kündig et al., 1996). CD28 co-stimulation will 
increase cell surface trafficking of glucose transporter GLUT1 (encoded by SLC2A1 gene) to 
facilitate glucose uptake in T lymphocytes (Frauwirth et al., 2002; Jacobs et al., 2008; Macintyre 
et al., 2014). The CD28 stimulation pathway is necessary to increase the effectiveness of current 
cancer immunotherapies. For example, Kamphorst et al., (2017) conducted a study exploring an 
immunotherapy technique that used a monoclonal antibody against PD-1 on exhausted cytotoxic 
T cells in attempts to rescue them. They found that in a tumor microenvironment, infiltrating CD8 
T cells are suppressed by the tumor through their interaction with PD-1. In their study, they used 
a murine model of lifelong chronic lymphocytic choriomeningitis virus infection to demonstrate 
that the activation, proliferation and rescue of infiltrating cytotoxic T cells from the tumor 
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microenvironment, relied on CD28 co-stimulation (Kamphorst et al., 2017). These studies 
suggested that glucose metabolism is mediated by CD28 co-stimulation and is a vital aspect of 




Metabolites such as glucose are a limiting factor in sustaining a strong immune response. 
During division of all somatic cells, large quantities of building blocks are necessary for DNA 
synthesis, membrane biosynthesis and energy production (Alberts et al., 2009). Activated T 
lymphocytes require these building blocks to maintain their proliferative state (van Stipdonk et al., 
2003). Within two hours of activation with anti-CD3 and anti-CD28 antibodies in vitro, there is an 
increased expression of the GLUT1 to support an increase in glucose uptake. The importance of 
glucose metabolism was shown by using a knockout of GLUT1 gene in mice, which impairs T 
lymphocyte activation and proliferation (Macintyre et al., 2014). While most interphase and G0 
cells use oxidative phosphorylation (OXPHOS) to satisfy their metabolic needs, proliferating cells 
will use both OXPHOS and aerobic glycolysis. While the efficiency of ATP production is much 
lower in glycolysis, glucose is typically not rate-limiting and permits carbon to be shuttled to 
biomass production (Rashida Gnanaprakasam et al., 2018). There is evidence that proliferating 
helper T cells favor a biosynthetic metabolic program through aerobic glycolysis (Bental and 
Deutsch, 1993; Dumitru et al., 2018). Naïve T cells may circulate in the blood and lymph without 
ever coming across an antigen and will use OXPHOS to provide ATP for regular cell processes 
(Klein Geltink et al., 2018). A naïve T cell that comes in contact with an antigen-MHC complex 
will shift its metabolism towards biosynthetic pathways to satisfy the bioenergetically demanding 
process of proliferation and clonal expansion (Heiden et al., 2009; Lunt and Vander Heiden, 2011). 
The final product of glycolysis, pyruvate, is converted into lactate. This process, called the 
Warburg effect, was first described in cancer cells by Otto Warburg (Weinhouse et al., 1956) 
(Figure 3). Aerobic glycolysis also supports an increase in inflammatory cytokine production, 
which is important for immune activation and is a hallmark of helper T cell activity (Menk et al., 
2018). Although aerobic glycolysis is not necessarily efficient in producing ATP, it provides 




Figure 3 – Increased glycolysis (Warburg effect) 
Activated, highly proliferative cells often undergo a metabolic shift towards the use of glycolysis 
(even in the presence of oxygen) to produce lactate. This is called the Warburg effect. Glucose is 
broken down to produce pyruvate and lactate. Lactate is excreted from the cell, while the NAD+ 
that was reduced is used again in glycolysis. Pyruvate also has the ability to enter the TCA cycle. 
While ATP production is minimal compared to OXPHOS, biosynthetic precursors are made to 




Pentose phosphate pathway and serine biosynthesis pathway intermediates are used to replicate 
DNA, synthesize phospholipids for new cell membranes and translate proteins necessary for rapid 
cell division (Wang et al., 2011). Glucose can also be converted into acetyl-CoA for lipid synthesis 
(DeBerardinis et al., 2008). Utilizing glucose as a precursor for substrate production is the 
backbone for an efficient and uninterrupted T lymphocyte expansion (Jacobs et al., 2008). 
An influx of metabolites is required to orchestrate T lymphocyte proliferation. Helper T 
cell proliferation relies on glucose and glutamine for energy and for building biomass. Glucose 
influx creates an environment within the cell that is hypertonic to the surrounding medium (blood 
or lymph). Therefore glucose uptake at these high rates can be osmotically unstable for the cell 
and excess glucose must be stored in a way that is efficient for proliferating helper T cells. 
 
1.7 Glycogen as a source for glucose storage and more 
Glycogen is a branched polymer of glucose used for energy storage in a wide variety of 
organisms (Roach et al., 2012). When energy levels are high, excess glucose is stored in the form 
of glycogen, which is triggered through the insulin pathway (Fadista et al., 2014). In contrast, in 
times of low energy, glucagon and epinephrine signal glycogen breakdown which then feeds 
glucose into metabolic pathways to produce energy and other by-products (Carroll et al., 1956). 
To form glycogen, glucose is first phosphorylated to make glucose 6-phosphate (G6-P). G6-P can 
also be derived through gluconeogenesis, which is controlled by the enzyme phosphoenolpyruvate 
carboxylase-1 (Figure 4). G6-P will need to be converted to glucose 1-phosphate (catalyzed by 
Phosphoglucomutase; PGM) and then UDP-glucose (catalyzed by UDP-glucose-
pyrophosphorylase; UGP) before glycogen polymer synthesis (glycogenesis) can begin. 
Glycogenin (GYG1) proteins initiate polymerization of the first two glucose monomers, through 
𝛼1-4 glycosidic linkages, which are then extended by the action of glycogen synthase (encoded by 
GYS1 and GYS2; Figure 4 and 5). The glycogen branching enzyme causes the formation of 𝛼1-6 
linkages (Figure 5). This enzymatic pathway results in a highly branched polymer that has been 
reported to have a molecular mass of ~107 kDa with a diameter of ~44nm (Goldsmith et al., 1982). 
Glycogen polymers can be seen as rosette-like particles through electron microscopy and are dark 
purple granules when subject to periodic acid Schiff (PAS) staining (Drochmans, 1962; Quaglino 




Figure 4 – Glycogen synthesis starting from glucose 
This schematic describes the synthesis of a new glycogen polymer starting with glucose. Glucose 
is first converted to G6-P. This can be derived as shown here by a glucokinase or directly from 
gluconeogenesis. PGM enzyme catalyzes the phosphate change from the 6C to the 1C on the 
glucose monomer. Addition of Uridine Diphosphate is catalyzed by UGP enzyme to form UDP-
glucose. Glycogenin acts as a primer to bring the first two UDP-glucose monomers together to 
form a short chain glycogen dimer. GYG is needed only until the chain reaches about eight glucose 
monomers. Addition of consecutive monomers and branches are catalyzed by glycogen synthase 
and glycogen branching enzyme respectively. This figure was created by Brandon Stopnicki using 





Figure 5 – Schematic of glycogen bonding and branching pattern 
Glycogen synthase, encoded by the GYS gene, adds UDP-glucose monomers to the growing chain 
at the 4C hydroxyl, forming 𝛼1,4 glycosidic bonds. Glycogen phosphorylase breaks down 
glycogen into G1P, which can then be used in a variety of pathways after being converted to G6P. 
Addition to the 6’ C is carried out by Glycogen branching enzyme, which makes 𝛼1,6 glycosidic 
bond and is encoded by GBE1 gene. Glycogen phosphorylase removes residues until there is a 
chain of 4 glucose monomers. The glycogen debranching enzyme (encoded by AGL gene) must 
break the 𝛼1,6 glycosidic bond before the phosphorylase can continue. This figure was created by 
Brandon Stopnicki using Berg et al., 2010 as reference. 
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caused by glycogen phosphorylase which de-polymerizes 𝛼1-4 linked glucose monomers followed 
by glucosyltransferase and amyloglucosidases. 𝛼-amylase can also be used to break down the 
glycosidic linkages in glycogen. This is followed by conversion of α1-6 positions into α1-4 
linkages for removal by glycogen phosphorylase which is encoded by the gene PYG (isoforms for 
PYG include, PYGB, PYGL and PYGM) (Berg et al., 2010). In humans and other mammals, 
glycogen is typically stored and manufactured in the liver, however glycogen has also been found 
in non-hepatic tissues such as muscles, brain cells and immune cells. 
Glycogen is an important metabolic regulator for a variety of non-hepatic cells. In 
astrocytes (neuroglial cells), glycogen is converted to glucose which is then processed into l-lactate 
to fuel neurons and other glial cells (Suzuki et al., 2011). Lactate, and consequently glucose, is 
important for astrocytes since they shuttle this lactate to neurons. Glucose uptake in reactive 
astrocytes, induced by oxygen-glucose deprivation, was monitored using the fluorescent glucose 
analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-deoxyglucose (2-NBDG). It was 
determined that glucose uptake was increased in reactive astrocytes (Chen et al., 2015). Surplus 
of glucose is stored as glycogen in astrocytes as a “energy buffer” in case of low-glucose levels 
(Brown et al., 2003; Waitt et al., 2017). Glycogen impairment in astrocytes negatively affects the 
central nervous system. Specifically, impairments in glycogen dynamics have been implicated in 
processes involving memory formation in the hippocampus and its decreased content may 
contribute to a depression-like behaviour in rats  (Hertz and Chen, 2018; Horvat et al., 2017; 
Magistretti and Allaman, 2018; Newman et al., 2011; Zhao et al., 2017). Besides providing a 
supply for lactate, glycogen also provided precursors to form glutamate, which is an important 
neurotransmitter (Araque et al., 2014; Savtchouk and Volterra, 2018; Zhang et al., 2014). While 
there is substantial evidence that glycogen is important in glial cell functionality, glycogen is also 
required in other non-hepatic cells. 
Glycogen has been found to modulate the function of certain immune cells. An increased 
glycogen storage in neutrophils is linked to an excessive innate immune response in Phd2-deficient 
mice. Blocking glycogenolysis with a glycogen phosphorylase inhibitor (GPI), caused an increase 
in the apoptosis rate of neutrophils (Sadiku et al., 2017). An overactive neutrophilic response is a 
hallmark of autoimmune conditions like asthma, allergy, lupus and rheumatoid arthritis (Courtney 
et al., 1999; Fu et al., 2013; Wipke and Allen, 2001). In PBMCs, it has been demonstrated that 
glycogen accumulates after 24-hours and was sustained over 72 hours with anti-CD3/anti-CD28 
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(Tabatabaei Shafiei, 2016). Most of what is known about glycogen in lymphocytes was discovered 
in the 1960s (Quaglino et al., 1962, 1964), when it was demonstrated that phytohaemagglutinin 
(PHA)-activated lymphocytes had a higher glycogen concentration than that of resting cells. They 
showed an increase of glycogen granules in immature pro-lymphocytic and blast cells, but they 
were not able to conclude this as a sufficient method for cancer diagnosis due to the contradictory 
findings of others (Jones et al., 1962; Leder and Donhuijsen, 1978). This left the topic of glycogen 
dynamics in healthy human T lymphocytes as a gap in the literature. Until recently, very little 
research into the biological relevance of glycogen storage and its use in immune cells had been 
conducted. Recent publications display evidence that glycogen increases in activated T 
lymphocytes and that glycogen plays important regulatory role in dendritic cells and cytotoxic 
CD8 T cells (Ma et al., 2018; Tabatabaei Shafiei, 2016; Thwe et al., 2017). There is a lack of data 
implicating glycogen as a requirement for helper T cell function. 
 
1.8 Experimental directions of thesis 
Using helper T cells, I explored the dynamics of glycogen storage in conditions where the 
T lymphocytes are activated. There is overwhelming data showing that in proliferating helper T 
cells an increase in glucose metabolism is crucial (Eiraku et al., 1998; Frauwirth et al., 2002; 
Greiner et al., 1994). The depletion of glucose during clonal expansion is not only a problem for 
energy availability but also for biomass accumulation. Glycogen is a means for glucose to remain 
constant even in low glucose environments. Inhibition of glycogenolysis or glycogenesis would 
be detrimental to the proliferation of helper T cells. A broader comprehension of the key cells in 
the adaptive immune response will help scientists better understand current therapies and to 
conceptualize future treatments for diseases. Helper T cells are arguably the most important 
adaptive immune cell; therefore, evidence of glycogen storage in these cells is important in 





CHAPTER 2 – HYPOTHESIS AND AIMS 
 
2.1 Hypothesis 
Glycogen accumulates in activated helper T cells and is necessary for T lymphocyte proliferation. 
 
2.2 Aims 
Below is indicated the manner in which I will test the overarching hypothesis. 
2.2.1 Aim 1 
Determine whether or not glycogen is found in helper T cells and if its amount changes 
when activated.  
2.2.2 Aim 2 
Determine if T lymphocyte proliferation is affected when glycogen metabolism is inhibited 
in T lymphocytes. 
2.2.3 Aim 3 
Determine if the expression of genes involved in the glycogen pathway is altered in helper 
T cells due to cell activation.  
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 CHAPTER 3 - MATERIALS AND METHODS 
 
3.1 PBMC isolation and participants 
The project was approved by Concordia University Ethics Review board (certificate # 
30009292). Participants were determined to be healthy individuals by self-reporting. Prior to the 
blood draw, participants were asked to sign a consent form. The consent form outlined the risks of 
giving blood, which included possible bruising and light-headedness. Blood was drawn by a 
phlebotomist through venipuncture and into anti-coagulant blood-collection tubes. All 
manipulations of PBMCs were done in a biosafety cabinet. PBMCs were isolated using a density 
gradient centrifugation technique with Ficoll-Paque PLUS (GE Healthcare Biosciences) as 
described previously (Tabatabaei Shafiei et al., 2014). PBMCs can be found in the buffy coat layer 
that resulted from the centrifugation technique. A buffy coat is the cloudy white layer containing 
mononuclear lymphocytes that excludes red blood cells, platelets, neutrophils, and other 
polymorphonuclear cells. PBMCs were counted using trypan blue solution (ThermoFisher 
Scientific) and then stored at 2x107 cells/aliquot in -80℃. Trypan blue counting was also used to 
assess viability. Trypan solution was added to equal volume of PBMCs and mixed. The suspension 
was then transferred to a haemocytometer and analyzed with the Leica DM2000 microscope. Dead 
cells took up trypan dye and appeared blue. Percent viability was calculated using Formula 1 (see 
Appendix). Once cells were counted and viability was assessed, the cells were placed in culture. 
 
3.2 Cell culture conditions, activation and treatments 
PBMCs were cultured in sterile round bottom 96-well plates with complete media, which 
included Roswell Park Memorial Institution (RPMI) 1640 medium, 11mM D-glucose, 10% fetal 
bovine serum (FBS), 1mM penicillin/streptomycin and 1mM L-glutamine. D-glucose is in excess 
in the complete RPMI (11mM) whereas the physiological blood glucose levels are around 5.5mM 
(Güemes et al., 2016) For figure 6, cells were cultured in 24-well flat bottom culture plates to 
facilitate imaging. PBMCs were activated with phorbol 12-myristate 13-acetate (PMA; 2ng/mL; 
Sigma-Aldrich) and anti-CD3 (0.1𝜇g/mL; eBioscience). There is evidence that PMA can activate 
PKC directly (Robinson, 1992). PMA is not a specific activator of T lymphocytes which suggests 
that is will activate most cell types within the PBMC suspension. Therefore, PBMCs were also 
 23 
activated with specific activator of T lymphocytes, monoclonal anti-CD3 and anti-CD28 
(eBioscience; 0.1𝜇g/mL each). Cells were incubated at 37℃ with 5% CO2 for 24 and 48-hours. 
Isolated helper T cells were activated with anti-CD3/anti-CD28 dynabeads (ThermoFisher 
Scientific). Dynabeads were washed prior to use with recommended buffer (phosphate buffered 
saline (PBS), 0.1% BSA and 2mM EDTA pH 7.4). Prior to downstream manipulation, the cell 
suspension was removed. The plate was placed on a magnet to ensure the dynabeads stuck to the 
bottom of the wells and were not removed with the cell suspension. 
To inhibit glycogen breakdown, PBMCs were cultured with GPI (BAYU6751, 0.5𝜇M) for 
48 hours before being harvested and stained with PAS. PBMCs were cultured using complete 
RPMI media with low serum (1% FBS). The effect of GPI on proliferation was assessed through 
flow cytometry. 
For astrocyte work, foetal human brain tissue was provided by the Albert Einstein College 
of Medicine (Bronx, NY, USA) in accordance with Albert Einstein College of Medicine and 
McGill University institutional review boards. Astrocytes from the aforementioned tissue were 
isolated at the Montreal Neurological Institute’s Neuroimmunology unit. All experiments 
involving astrocytes were done in the neuroimmunology unit at the Montreal Neurological 
Institute under the supervision of Dr. Luke Healy and his staff. Astrocyte-enriched cultures were 
prepared by obtaining a dispersed cell suspension from the foetal brain tissue by trypsinization and 
mechanical disruption. The cells were then cultured in Dulbecco Modified Eagle Media (DMEM) 
with 10% foetal bovine serum (FBS), pen/strep, L-glutamine, with at least three passages before 
use. The astrocytes were seeded on thermanox coverslips (ThermoFisher Scientific) in 24-well 
plates and used upon confluency. Astrocytes were made reactive with the addition of cytokine IL-
1𝛽 (1ng/mL) and then incubated for 24-hours at 37℃ with 5% CO2.  
 
3.3 Glycogen visualization 
3.3.1 2-NBDG 
 
Glycogen was visualized in helper T cells and PBMCs through both fluorescence and 
histological staining. Activated PBMCs were pulsed with 50𝜇M of 2-(N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl) amino)-2-deoxyglucose (2-NBDG; ThermoFisher Scientific) for 2 hours in D-
glucose-free RPMI. Glucose-free RPMI was used to prevent glucose uptake competition with 2-
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NBDG. 2-NBDG is a fluorescent glucose-analog that is commonly used to study glucose uptake. 
Cells were then washed and replaced with complete D-glucose RPMI (pen/strep, L-glutamine and 
10% FBS). Pulsation was crucial since, once 2-NBDG enters the cell, it becomes phosphorylated 
and cannot exit causing accumulation which is potentially cytotoxic for the cell. The optimal 
concentration and time of pulsation was determined using Jurkat T cell line by titration of 
increasing concentrations of 2-NBDG from 10𝜇M-500𝜇M. Cells were washed with ice-cold 1X-
PBS. PBMCs were similarly pulsed with 50 𝜇M of 2-NBDG for 1-hour in glucose-free RPMI 
(10% FBS). The PBMCs were washed and media was replaced with D-glucose complete RPMI 
(10% FBS) for 48-hours. Both Jurkat T cells and PBMCs were then visualized with the Leica DMi-
6000B fluorescent microscope with excitation/emission maxima ~465/540nm, respectively. 
Images were processed in Fiji software (Fiji is just ImageJ). Glycogen granules in PBMCs, muscle 
and human pluripotent stem cells (Chen et al., 2015a; Tabatabaei Shafiei et al., 2014), have a 
distinct punctate morphology, therefore glycogen was qualitatively defined through its 
morphological features. 
Glycogen was visualized in human foetal astrocytes using 2-NBDG. Astrocytes were 
starved of glucose for a minimum of 1-hour prior to 2-NBDG treatment. 2-NBDG (25µM) was 
then added to astrocyte cultures in 24-well plates for 1 hour with glucose-free DMEM (10% FBS). 
The cells were then washed (1XPBS) and media was replaced with D-glucose DMEM (10% FBS) 
for 24-hours. Cells were fixed with 4% paraformaldehyde for 10-15 minutes at room temperature. 
Astrocytes were then stained with Hoechst (blue) and Cy3-GFAP (Sigma-Aldrich). For Cy3-
GFAP intracellular staining, astrocytes were permeabilized in 0.3% triton X-100. Images were 
obtained on an inverted epi-fluorescent microscope at the Centre for Microscopy and Cellular 
Imaging (CMCI) located at Concordia University (Leica DMi-6000B). Resulting images were 
processed using Fiji software. 
 
3.3.2 Periodic acid Schiff’s histological stain 
Glycogen was also visualized using PAS reaction as described previously with small 
modifications (Tabatabaei Shafiei et al., 2014). Periodic acid oxidized the C-C bond in 
carbohydrates that have a free hydroxyl group. This resulted in dialdehydes which then react with 
the Schiff’s reagent forming a magenta-coloured complex that was monitored with light 
microscopy techniques and quantitatively analyzed with Fiji software (described below). The 
 25 
periodic acid selectively oxidizes polymers of high molecular weight and not low molecular weight 
water soluble monosaccharides such as glucose.  
PAS staining was done on both PBMCs and isolated helper T cells. PBMCs and isolated 
helper T cells were fixed with 4% paraformaldehyde prior to staining. Staining was done in 96-
well V-bottom culture plates to minimize cell loss that occurred when staining directly on a 
microscope slide. Cells were suspended in periodic acid and then washed twice with ddH2O. After 
the first washing step, the cells were resuspended in Schiff’s reagent and incubated in the dark for 
15 minutes. Cells were washed 4 times. Each wash step required 30 seconds of agitation in ddH2O. 
Cells were then placed on a glass slide and left to air dry. Once the slides were dry, a drop of 
toluene mounting media (Permount) was added on top of the cells and a coverslip was placed over 
it. Each slide was then sealed with clear nail polish. Images were taken using a Nikon Eclipse TiE 
and Leica DM2000. Resulting images were processed using Fiji software. 
 
3.3.3 Image processing 
Images of PBMCs and helper T cells that were stained with PAS were captured on a Nikon 
Eclipse TiE. 5 pictures were taken, in duplicates, for each slide (representing one participant 
sample). The bright field images were opened in Fiji software and the mean signal intensity and 
area of each cell was measured. For each replicate all the cells in the 5 images were measured for 
both signal intensity and for cell size measurements. Not all cells had the same background (inside 
the cell) staining intensity. Certain cells stained bright pink over the entire cell area. Only cells that 
had a faint pink background were chosen for analysis. This bias was introduced to eliminate the 
cells that had outlier levels of signal intensity. 
The mean signal intensity was measured using Fiji software. A macro (Figure S1) was 
designed that did the following. The image contrast was enhanced, and the green channel was split 
out. The green channel has the most contrast, which is why this channel was chosen. The image 
was blurred to hide small artifacts such as cell debris. Lastly, the macro told Fiji to threshold the 
images to find areas above 1500 pixels in size, which we can assume are cells. The cell areas are 
selected as regions of interest and measured on the grey scale for mean pixel intensity. These areas 
were not always cells, which is why each image was monitored for errors by me seeing that the 
region of interest was not debris or background staining. For cells at rest, the threshold was often 
too high and therefore the cells had to be selected by hand. 
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3.4 Amylase treatment 
Amylase powder (Sigma-Aldrich) was reconstituted as per manufacturer’s instructions and 
as described previously (Tabatabaei Shafiei, 2016). Helper T cells were activated with dynabeads 
and then fixed with 4% paraformaldehyde. The cells were then treated with 𝛼-amylase prior to 
being stained with PAS to digest glycogen. This condition was designated as the negative control. 
The helper T cells were incubated with amylase solution for 10 minutes. Cells were washed with 
1X-PBS and re-suspended in complete RPMI. These cells were subjected to glycogen visualization 
techniques as described above. 
 
3.5 CD4+CD3+ T lymphocyte isolation 
Using EasySep Human CD4+ T cell Isolation Kit (StemCell technologies), helper T cells 
(defined through the surface proteins CD4+CD3+) were isolated from PBMCs. This process is done 
through immunomagnetic negative selection by adding (according to supplier’s instructions) 
antibody cocktail (50𝜇L/mL) and magnetic spheres (50 𝜇g/mL) to PBMCs in suspension at 
5x107cells/mL in the recommended media (2% FBS, PBS, 0.2% EDTA). The negative selection 
antibody kit removed cells positive for CD8, CD14, CD15, CD16, CD19, CD36, CD56, CD123, 
TCR 𝛾/𝛿 and CD235a. Magnetic spheres were then added to the suspension. The solution was 
added to a magnetic column and the non-CD3+CD4+ were taken out of solution by the magnetic. 
The flow through was poured off and contained helper T cells. Purity was assessed via flow 
cytometry (Figure 9). 
 
3.6 Flow cytometry 
Purified helper T cells were labeled with anti-CD4 (PerCP) and anti-CD3 (APC) to 
determine the effectiveness of the negative selection. Each cell is represented on the 2D-histogram 
by a point. Side scatter (x-axis) represents cell complexity. A laser was shot at each cell 
individually as it passed through the fluidics section of the flow cytometer. Laser light hit the 
intracellular components, was scattered and then picked up by a specialized receptor. Forward 
scatter (y-axis) represents cell size. The light from the laser that is not shielded by the cell makes 
it to the receptor opposite the laser. Dead cells or cell debris are often small and are dense therefore 
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resulting in low light scatter (side scatter). Live cells were gated based on their size and complexity. 
Of the live lymphocytes, the double positive population (CD4+CD3+) was used for analysis and 
considered helper T cells. For the proliferation assay, CFSE was recorded via channel for FITC 
(𝜆=495nm). The dye entered the cell as CFDA-SE and was first converted to CFSE. CFSE then 
covalently labels long-lived proteins inside the cell (CF-protein). Each cell division resulted in the 
fluorescent signal diminishing by half, since the daughter cells obtained half the material of the 
original cell when it divided. This way, the extent of proliferation was quantitatively determined 
by the rate in which the signal degraded over time. The flow cytometry data was analyzed using 
FlowJo software (TreeStar). 
 
3.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was used to measure the concentration of released cytokine IL-17A. Standard 
sandwich ELISA was used (eBioscience). The steps were done according to manufacturer’s 
instructions. Capture antibody was incubated in a 96-well plate overnight for it to be stuck to the 
plate. The plate was washed and then blocked with assay diluent (10% FBS in 1XPBS) to eliminate 
any unspecific binding of the capture antibody. Blocking is followed by a series of washing steps 
(with wash buffer: PBS-tween). The samples were diluted and added to the wells, then incubated 
to let them bind to the capture antibody. Incubation was followed by a series of washes with wash 
buffer. The working detection antibody was added to the wells, which is specific to a portion of 
the protein of interest. The detection antibody is conjugated with horseradish peroxidase (SAv-
HRP). Another series of washes were done before adding substrate. HRP reacted with 3,3’5,5’-
tetramethylbenzidine (TMB) substrate to a form coloured product. The reaction was stopped using 
sulfuric acid (2N) yielding a yellow colour. The absorbance was read at 450nm (yellow) and 
570nm (used for wavelength correction). Wavelength correction was used to remove background 
emissions from the reading. Absorbance was proportional to the amount of protein added to the 
well. 
 
3.8 RNAseq analysis 
RNAseq data was obtained from GEO public NIH database. The authors of the datasets 
carried out the RNA sequencing in the following way: Total RNA from human helper T cells was 
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purified and converted into cDNA. Helper T cells were isolated from venous blood similarly to 
that of this thesis. Methods for RNA library formation and sequencing can be found in Gate et al., 
2018, and Komori et al., 2015. The authors purified total RNA and converted it into cDNA. The 
RNA was selected for size using electrophoresis and then libraries were amplified through PCR. 
Cluster generation and RNA sequencing was done using an Illumina HiSeq (for Gate et al., 2018) 
and Illumina GAIIx (for Komori et al., 2015). Sequenced reads were aligned to a reference genome 
(hg18 and hg19) and analyzed as described in the methods section of their manuscript (Gate et al., 
2018 and Komori et al., 2015). TPM (Gate et al., 2018) and RPKM (Komori et al., 2015) formulas 
were used to express the data. TPM and RPKM (also FPKM, RPM and raw read counts could be 
used) are both expression units that provide a means to express the abundance of a transcript within 
a sample. While there are benefits for using either RPKM or TPM to express RNAseq data TPM 
has arisen as the more reliable method. The main differences between RPKM and TPM are that in 
TPM formula, normalization for gene length occurs first where RPKM normalizes for sequencing 
depth first. The outputs for the sum of all the TPMs in the sample are the same, making them easily 
comparable between samples (Formula 3). For different RPKM outputs, the proportions may be 
different between samples making them potentially more difficult to compare. Fold-change for the 
expression levels of genes involved in glycogen dynamics was determined for each participant. 
Error bars represent sequencing runs performed (n=6 for both studies). Raw data can be found 




Statistical analysis with multiple comparisons was done using a one-way ANOVA (p < 
0.05). Post hoc Tukey’s multiple comparison test was used to determine the differences between 
means. For statistical analysis between two groups, a paired Student’s t-test was performed. 
Outliers in the data were removed upon the completion of a Grubb’s test. The level of significance 
is indicated by *p < 0.05 and was significantly different. At times it is indicated that, **p < 0.01, 




CHAPTER 4 – RESULTS 
 
 
4.1 PMA activation caused glycogen accumulation in PBMCs 
To test my hypothesis, I established protocols to simulate an immune response in vitro 
using standard activating stimuli. The PBMCs were activated with PMA and anti-CD3, and then 
the cells were observed with light microscopy to confirm their activation. PBMCs have the 
tendency to cluster together when activated. Using light microscopy, it is possible to observe these 
PBMC clusters. For the first experiment, PBMCs were incubated for 24 hours in complete media 
with no stimulus to establish the baseline negative control (Figure 6A). These non-activated 
PBMCs were dispersed across the bottom of the cell culture plate and formed little to no clustering. 
PBMCs activated with PMA and anti-CD3 for 24-hours formed clusters after activation, which 
were indicated by arrows in the image (Figure 6B). For the second experiment, PBMCs were 
incubated for 24-hours in complete media without stimulus to establish a baseline negative control 
(Figure 6C). PBMCs activated with soluble anti-CD3 and anti-CD28 antibodies formed clusters 
(Figure 6D). This data suggests that the PBMCs treated with PMA+anti-CD3 and soluble 
antibodies (anti-CD3/anti-CD28) were appropriately activated since clustering is a hallmark of T 
lymphocyte activation. 
 In the laboratory's previous results, glycogen was shown in PBMC. My first step was to 
modify the procedure to accommodate more test groups by switching from a slide-based technique 
to a 96-well plate-based technique. With this modification I could increase the biological replicates 
and compare more groups. I confirmed that the PAS-staining results could be reproduced with the 
modified methodology. PBMCs were cultured for 24 and 48-hours with or without PMA+anti-
CD3. Subsequently, PBMCs were stained for glycogen using PAS stain. PAS reacts with the 
glycogen polymer turning it a purple color. According to previous findings, glycogen specifically 
appears as diffuse signal throughout the cell, and in punctate purple granules. Non-activated 
PBMCs had no punctate purple granules and low diffuse signals (Figure 7A). In contrast, activated 
PBMCs had an intense signal and visible punctate granules (Figure 7B). Resolved granules were 
formed 48-hour after activation with PMA+anti-CD3. An increase in mean signal intensity 
indicated PAS-glycogen increase. The more glycogen granules there were in the cell, the higher 
the signal intensity for PAS was. There was a trend to increase in mean signal intensity for PAS-
glycogen after 24 and 48-hours compared to non-activated PBMCs (Figure 7C). Lastly, the 
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PBMCs that were activated with PMA and anti-CD3 for 24 and 48-hours showed a trend to 
increase in cell area (𝜇m2), which provided further evidence of their activation since activated cell 
become larger due to growth and DNA duplication (Figure 7D). This data showed that glycogen 








Figure 6 – Evidence that PBMCs were activated at 24-hour time-point 
PBMCs were culture for 24-hours with and without activation conditions and then analyzed by 
light microscopy. The PBMCs were either cultured A) without activation conditions or treated 
with B) PMA+anti-CD3. PBMCs were either cultured C) without activation conditions or treated 









Figure 7 –Evidence of glycogen accumulation in PMA-activated PBMCs 
PBMCs were cultured for 24 and 48-hours with PMA plus anti-CD3. PBMCs were cultured A) 
without-activation conditions or with B) PMA+anti-CD3. C) Signal intensity was recorded using 
the macro from Appendix 1 (Figure S1) in Fiji software. D) PBMC area (𝜇m2) was calculated from 
the regions of interest determined by Fiji software (macro). Error bars are representative of the SD 
between 1 experiment with 5 technical replicates. Magnification = 40x.  
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4.2 Activation with anti-CD3 and anti-CD28 caused glycogen accumulation in PBMCs 
In the previous section, I activated all cells in PBMC suspension with a combination of 
PMA and anti-CD3. Since PMA is a chemical and directly activates PKC it is not as biologically 
relevant as using CD28 stimulation, and PMA can activate other cells in the PBMC. Thus, the 
PMA activation conditions (even in the presence of anti-CD3) did not provide reliable evidence of 
glycogen dynamics in T lymphocytes. Therefore, I examined how the glycogen dynamics were 
regulated in T lymphocytes by using soluble anti-CD3 and anti-CD28. PBMCs were activated for 
24 and 48-hours. The PBMCs were then collected, and the glycogen was stained using PAS. After 
glycogen staining, PBMCs were imaged using light microscopy. Punctate purple granules 
appeared in PBMCs that were cultured for 24-hours with anti-CD3/anti-CD28 whereas control 
PBMCs had no visible granulation (Figure 8A, B). Punctate purple granules were observed in 
PBMCs 48-hours after activation (Figure 8C). PBMCs that were not activated, had no granule 
formation after 48-hours (Figure 8D). The signal intensity of PAS was analyzed. The mean signal 
intensity of the PAS stain represents the signal from the diffuse staining and the punctate granules 
of glycogen inside the cell. Activation of PBMCs increased the glycogen signal intensity for both 
24 and 48-hour time points compared to the respective non-activated controls (Figure 8E). 
Activation of PBMCs increased the area of the cells had a trend to increase when they were 
activated with anti-CD3/anti-CD28 for 24-hour and significantly increased in area after 48-hours 
(Figure 8F). An increase in cell area is an indicator of cell activation. This data demonstrates that 






Figure 8 –Evidence of glycogen accumulation in PBMCs activated with soluble antibodies  
PBMCs were cultured for 24 and 48-hours with soluble anti-CD3 and anti-CD28. PBMCs were 
cultured for 24-hours A) without soluble antibodies or B) with soluble antibodies. PBMCs were in 
parallel, PBMCs were cultured for 48-hours C) without soluble antibodies or D) with soluble 
antibodies. PBMCs were then stained with PAS at the indicated time points E) The mean signal 
intensity for PAS-glycogen was calculated in Fiji (n=5 different participants) at time points of 24 
and 48-hours. F) Area (𝜇m2) was measured per condition and time point for each individual (n=5 




4.3 Isolated Helper CD4+ T cells accumulate glycogen when activated in vitro 
The focus of this thesis was to investigate glycogen dynamics in purified human helper T 
cells. The PBMCs tested comprised of a mix of T lymphocytes and other immune cells such as 
natural killer cells, B cells, monocytes and dendritic cells. The glycogen I detected could have 
been from the non-T-cells in PBMC suspension. In order to measure glycogen, helper T cells were 
purified from PBMCs and used for the subsequent experiments. Purified helper T cells were 
identified by their surface proteins CD4 and CD3 and assessed through flow cytometry. 
The flow cytometer provided information on the properties of the cells such as cell size, 
complexity and protein composition. Based on these properties it is possible to distinguish 
populations of cells on the 2D histogram output. For example, live cells appear high on side scatter 
(indicator of cell complexity) because of the complexity within the cell. Dead cells or debris 
clustered at the origin of the y-axis and x-axis. Live cells represented over 98% of the 
representative sample which shows a low level of dead cell/debris (Figure 9A). The proportion of 
these cells that were helper T cells (that express CD4 and CD3 in the upper right quadrant) were 
over 97% (Figure 9B). When the data was combined from all the experiments I did, the mean live 
cells obtained were 92.36% +/- 6.5%, while the helper T cells were 96.25% +/- 1.89 (Figure 9C). 




Figure 9 – CD4+CD3+ helper T cell purity confirmation 
Helper T cell enrichment was confirmed by flow cytometry. A) Live, lymphocyte cells were 
selected to exclude the dead cells or debris found closer to the intersection of the x-axis and y-axis. 
B) Cells were stained with fluorescent anti-CD3 (APC) and anti-CD4 (PerCP). Gates were 
established to select the double positive population (Q2) CD4+CD3+. C) This represents the 
percentage of the total amount of cells found to be either lymphocytes or fell into the Q1 (CD4-




Next, glycogen in purified helper T cells was detected using PAS staining. The baseline 
for PAS-glycogen stain at the 24-hour time point was established using non-activated helper T 
cells (Figure 10A). Helper T cells that were activated for 24-hours with dynabeads (coated with 
CD3 and CD28), showed PAS-glycogen granule accumulation (Figure 10B). The baseline for 
PAS-glycogen at the 48-hour time point was established using non-activated helper T cells (Figure 
10C). Helper T cells that were activated for 48-hours showed PAS-stained granules (Figure 10D). 
The mean signal intensity of PAS-glycogen had a trend to increase after 24-hours of activation 
with dynabeads (Figure 10E). The mean signal intensity for PAS-glycogen significantly increased 
in helper T cells activated with dynabeads for 48-hours compared to the non-activated control 
(Figure 10E). Activated helper T cells significantly increased in cell area when compared to the 
non-activated control for both 24 and 48-hour time points (Figure 10F). As a negative control, 
helper T cells were treated with 𝛼-amylase prior to PAS-glycogen staining. The 𝛼-amylase 
digested the glycogen prior to staining and therefore was used as a negative control for the PAS 
histological staining technique. There was no significant difference between the mean signal 
intensity of activated helper T cells treated with the 𝛼-amylase and the non-activated helper T cells 
(Figure 10G). Non-activated helper T cells and the 𝛼-amylase negative control had a significantly 
lower mean signal intensity to activated helper T cells that were not treated with 𝛼-amylase (Figure 







Figure 10 – Helper T cells accumulated glycogen upon activation 
Purified helper T cells were cultured for 24 and 48-hours with dynabeads coated with CD3 and 
CD28, then stained with PAS. Helper T cells were placed in culture A) without dynabeads or B) 
with dynabeads for 24-hours. In parallel, helper T cells were placed in culture C) without 
dynabeads or D) with dynabeads for 48-hours. The mean PAS-glycogen signal intensity was 
calculated using Fiji software (n=5 different participants) at time points of E) 24 and 48-hours. F) 
The cell area (𝜇m2) was measured per condition and time point of each individual (n=5 different 
participants). G) After being cultured for 48-hours, helper T cells were treated with 𝛼-amylase in 
order to digest glycogen prior to staining as the negative control (data pooled from 2 participants 
done in duplicates). Magnification = 40x 
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4.4 Glycogen breakdown inhibition alters the proliferation profile of PBMCs in vitro 
The function of glycogen storage in helper T cell is not well known. The highly 
proliferative property of T lymphocytes is one of their defining features. Therefore, it was 
important to explore the way glycogen metabolism could affect proliferation. PBMCs were 
activated with T lymphocyte specific activators (anti-CD3 and anti-CD28) with or without GPI. 
GPI works as a potent competitive inhibitor for glycogen phosphorylase and has been shown to 
inhibit glucagon induced glycogenolysis in hepatocytes in vitro (Klabunde et al., 2005). The 
effects of GPI on proliferation and cytokine production were measured. It can be speculated that 
GPI inhibited glycogenolysis and therefore resulted in the inhibition of glycogen-derived glucose 
supply to the cell. Non-activated PBMCs were used to establish a baseline control for PAS-
glycogen staining (Figure 11A). PBMCs accumulated PAS-glycogen granules when activated with 
or without GPI (Figure 11, B and C). Mean signal intensity for PAS-glycogen increased by 
approximately 2-fold in activated PBMCs treated with GPI compared to the non-activated control 
(Figure 11D). To measure the effect of GPI on proliferation, PBMCs were activated in the presence 
of GPI for 4 days in media with 1% serum. The PBMCs were treated with CFDA-SE to monitor 
proliferation (explained further in section 3.6). PBMCs, activated in the presence of GPI 
proliferated 10% less (p < 0.01) than PBMCs activated without GPI (Figure 11E). Activated 
PBMCs with GPI proliferated almost 20% more than non-activated PBMCs (Figure 11E). GPI 
affected the production of pro-inflammatory cytokine IL-17A. Activated PBMCs that were treated 
with GPI had a trend to decrease in IL-17A production when compared to activated cells without 
GPI treatment (Figure 11F). This data suggests that glycogenolysis may play a role in proliferation 






Figure 11 –Effect of GPI on glycogen accumulation and proliferation in activated PBMCs  
PBMCs were either A) not activated, B) activated with soluble antibodies or C) activated with 
soluble antibodies with the addition of GPI. PBMCs were then stained for glycogen using PAS. 
D) The mean signal intensity for PAS-glycogen was analyzed with Fiji software. E) Proliferation 
was assessed using CFDA-SE and was analyzed via Flow cytometry. F) IL-17A concentration in 
the supernatant was measured via ELISA. For this experiment. PBMCs were grown in RPMI with 




4.6 2-NBDG is useful in human astrocytes but not in lymphocytes to detect glycogen 
Besides for PAS histological stain, there are very few established methods for visualizing 
glycogen in helper T cells. 2-NBDG is a fluorescent analog of glucose that is primarily used to 
record glucose uptake. I wanted to test whether 2-NBDG could incorporate itself into the glycogen 
polymer in the helper T cells and therefore provide a more versatile means to visualize glycogen 
than PAS. To test this method, human astrocytes were used as a control. There is literature showing 
that glycogen is important for astrocyte cell function. 24-hours prior to manipulation, astrocytes 
were made reactive by adding IL-1𝛽 cytokine. Reactive astrocytes take up glucose at a higher rate 
than non-reactive astrocytes (Chen et al., 2015b). Both reactive and non-reactive astrocytes took 
up 2-NBDG. In resting astrocytes, fluorescence was dispersed throughout the cytoplasm (Figure 
12, left panels). Reactive astrocytes had punctate granules of 2-NBDG (Figure 12, right panels). 
The punctate granules seen in the cytoplasm of the astrocytes are most likely glycogen molecules. 
The conclusions are two-fold; 2-NBDG can detect glycogen in astrocytes, and astrocytes 
accumulate glycogen when made reactive with pro-inflammatory cytokine IL-1𝛽.  
Since 2-NBDG was incorporated into glycogen in reactive astrocytes, the next steps were 
to translate this method to helper T cells. Before using primary T lymphocytes, Jurkat T cells were 
used as a control. Jurkat T cells are an immortalized T lymphocyte cell line commonly used for in 
vitro experimentation. These cells are simple to culture and proliferate highly when activated. 
Jurkat T cells were cultured with 2-NBDG in activation conditions for 24 and 48-hours. Activated 
Jurkat T cells seemed to have taken up 2-NBDG and formed granules (Figure 13 right panels). 
However, activated Jurkat T cells, in the absence of 2-NBDG, had high background fluorescence 
in the green channel (Figure 13 middle panels). A similar signal was observed in non-activated 
Jurkat T cells (Figure 13 left panels). This indicated that Jurkat T cells either are auto-fluorescent 
for this wavelength or that Jurkat T cells were not taking up 2-NBDG as efficiently as foetal 






Figure 12 – 2-NBDG is incorporated into glycogen in reactive human astrocytes 
Immunofluorescent images of foetal human astrocytes show 2-NBDG (green) accumulation and 
granule formation inside the cells. GFAP (red), an intermediate filament only in astrocytes, shows 
the cell shape. Overlap between 2-NBDG granules and GFAP would indicate the granules are 





Figure 13 – 2-NBDG in Jurkat T cells 
Immunofluorescent images of Jurkat T cells show 2-NBDG (green) accumulating and forming 
granules inside the cells during activation. However, Jurkat T cells are auto-fluorescent and 
therefore 2-NBDG is currently an unreliable method for measuring glycogen in helper T cells. 2-
NBDG signal (green) is observed in control conditions (no 2-NBDG). DAPI (blue) was used as a 
nuclear stain. Magnification = 60x 
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This data suggests that 2-NBDG was not yet suitable to measure glycogen in Jurkat T cells and 
PBMCs (Figure S3). More optimization is required for 2-NBDG to become an efficient method 
for glycogen measurement in T lymphocytes. 
 
4.5 RNA expression for genes involved in glycogen dynamics in helper T cells 
My results indicated that glycogen was important for T lymphocyte metabolism. I sought 
to determine to what extent glycogen genes were being differentially expressed during helper T 
cell activation. NIH’s Genome Expression Omnibus (GEO) is a public repository for genomic data 
submissions. I compiled data from two data sets (Gate et al., 2018; Komori et al., 2015). RNAseq 
data was aligned and processed by the authors and was made public in a ready to read file format. 
Experimental set-up was similar for both data sets. However, the two data sets were not 
comparable due to the formulas used to report the results (RPKM vs. TPM). From the data sets I 
compared the expression of genes involved in the glycogen pathway. Gene expressions from 
activated helper T cells with dynabeads were compared to non-activated helper T cells. RNA 
expression varied in activated naïve helper T cells for 48-hours compared to non-activated helper 
T cells. For the Komori et al., 2015 data set, glycogen synthase isotypes (GYS1 and GYS2) 
increased by ~2-fold when helper T cells were activated for 48-hours (Figure 14A). Brain glycogen 
phosphorylase (PYGB) increased in activated helper T cells while liver and muscle glycogen 
phosphorylase (PYGL and PYGM) decreased in expression when activated (Figure 14B). 
Phosphoglucomutase (PGM1 and PGM2) expression increased by ~4-fold and ~2-fold, 
respectively (Figure 14C). In helper T cells, UDP-glucose pyrophosphorylase 2 (UGP2), 
glycogenin (GYG1) and glucose channel 1 (SLC2A1) increased by ~1.5-fold, ~0.2-fold and ~0.7-
fold respectively when activated (Figure 14D). For the Gate et al., 2018 data set, GYS1 gene 
increased in expression by ~2-fold when helper T cells were activated (Figure 15A). GYS2 showed 
no change in expression (Figure 15A). PYGB increased in activated helper T cells by ~1-fold while 
the expression of PYGL and PYGM decreased or remained mostly unchanged when activated 
(Figure 15B). PGM1 and PGM2 expression increased by ~2-fold and ~4-fold respectively (Figure 
15C). In helper T cells, UGP2, GYG1 and SLC2A1 increased by <1-fold, <1-fold and ~4-fold 
respectively when activated (Figure 15D). These data sets provided evidence to the difference in 




Figure 14 – Gene expression for transcripts involved in glycogen dynamics (derived from 
Komori et al., 2015) 
RNAseq data was modified from Komori et al., 2015 obtained from the GEO public database. 
RNAseq data was represented as RPKM. The formula to determine RPKM can be found in 
Appendix 1 formula 2. The fold-change between non-activated and activated helper T cells was 
calculated. A) Change of mRNA expression for two isoforms of glycogen synthase (GYS1 and 
GYS2). B) Change of mRNA expression for three isoforms of glycogen phosphorylase; brain, liver 
and muscle (PYGB, PYGL and PYGM). C) Change of mRNA expression for two isoforms of 
phosphoglucomutase (PGM1 and PGM2). D) Change of mRNA expression for three proteins 
involved in glycogen dynamics: UDP-glucose pyrophosphorylase 2, glycogenin 1 and glucose 
transporter 1 (UGP2, GYG1 and SLC2A1). Error bars represent the standard error of the mean 




Figure 15 - Gene expression for transcripts involved in glycogen dynamics (derived from 
Gate et al., 2018) 
RNAseq data was modified from Gate et al., 2018 obtained from the GEO database from. RNAseq 
data was represented as TPM. The formula to determine TPM can be found in Appendix 1 formula 
3. The fold-change between non-activated and activated helper T cells was calculated. A) Change 
of mRNA expression for two isoforms of glycogen synthase (GYS1 and GYS2). B) Change of 
mRNA expression for three isoforms of glycogen phosphorylase; brain, liver and muscle (PYGB, 
PYGL and PYGM). C) Change of mRNA expression for two isoforms of phosphoglucomutase 
(PGM1 and PGM2). D) Change of mRNA expression for three proteins involved in glycogen 
dynamics: UDP-glucose pyrophosphorylase 2, glycogenin 1 and glucose transporter 1 (UGP2, 
GYG1 and SLC2A1). Error bars represent SEM. Raw data can be found using GEO accession 
number GSE86888. 
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CHAPTER 5 – DISCUSSION 
  
The purpose of this thesis was to investigate the dynamics of glycogen in purified helper T 
cells. The first aim was to observe glycogen accumulation in activated helper T cells. The second 
aim was to assess the effects of glycogenolysis inhibition on T lymphocyte proliferation and 
cytokine production. The third aim was to investigate the change in expression of genes involved 
in glycogen dynamics in activated helper T cells. This is one of the first times glycogen dynamics 
in helper T cells was studied, while successfully demonstrating its presence and significance to 
effector function. 
 
5.1 Glycogen dynamics in PBMCs 
The study of glycogen dynamics in activated PBMCs sheds light on the larger role 
glycogen plays in an immune response. PBMCs were stimulated in vitro with either small molecule 
PMA or soluble antibodies. It is speculated that PMA directly acted upon PKC and therefore 
activated all cell types in suspension, where the soluble antibodies provided the necessary signals 
for activation of the T lymphocytes within PBMC suspensions. Activated PBMCs, that were 
stained with PAS, had purple glycogen granules dispersed throughout the cytoplasm. An increase 
in mean signal intensity of the PAS stain within the PBMCs confirmed that glycogen stores had 
increased due to activation, which supports previous findings. Although there was an overall 
increase in PAS-glycogen, not all activated PBMCs contained granules. There was no consistent 
pattern to determine which cells contained granules (location of granules within the cell or size 
and morphology of the cells). Some PBMCs showed purple punctate granulation patterns while 
others had diffused purple staining (Figure S2). This sporadic staining trend is consistent with 
previous literature (Tabatabaei Shafiei, 2016). 
The cells that had PAS-glycogen did not always have punctate granules; certain cells also 
had diffuse staining. The reason for differences in staining patterns for PAS-glycogen is still 
unclear. 24-hours after activation, the staining was prominently diffuse, whereas after 48-hours 
there appeared to be more resolved punctate granules. Not all of the activated cells had glycogen 
granules (either diffuse or granulated). A lack of glycogen accumulation in some cells could be 
due to several factors. While naïve T cells made up the majority of T lymphocytes in the extracted 
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blood, there is a fraction of differentiated helper T cells (Th1, Th2, Th17, Th9, Th22 and Treg), 
cytotoxic T cells and memory T cells that could be present in suspension (Kleiveland, 2015). 
Activation of PBMCs with anti-CD3/anti-CD28 would have resulted in the activation of a 
heterogeneous population of T lymphocytes. Each T lymphocyte subset could have a varied use 
for glycogen. Differentiated T lymphocytes are identified by their surface proteins and expression 
of different cytokines. It is possible that differentiated T lymphocytes use glycogen for different 
reasons depending on their cell type and life stage at the time of activation. As an example, there 
could have been cytotoxic T cells present in the suspension. There is evidence that glycogen plays 
a role in the ability for CD8 cytotoxic T cells to differentiate into memory cells (Ma et al., 2018).   
Isolated PBMCs contained a high ratio of T lymphocytes but were also composed of B 
lymphocytes, natural killer cells, monocytes and a small percentage of DCs. Prior knowledge of 
glycogen dynamics exists for DCs, and cytotoxic T cells, meaning the glycogen accumulation 
could very well be coming from cells that are not T lymphocytes. Monocytes could be stimulated 
by IL-17A and may be an explanation for the larger cells captured in figure 8D that contained 
glycogen granules (Erbel et al., 2014). The anti-CD3/CD28 activation provided validation to the 
altered PAS-staining technique and therefore endorsed the testing of glycogen dynamics on 
isolated helper T cells. 
 
5.2 Glycogen dynamics in activated helper T cells 
 The use of purified populations of helper T cells was important to reduce unwanted 
discrepancies coming from a mixed population of cells. Isolated helper T cells accumulated 
glycogen when activated in vitro. There were differences in glycogen granule morphology 
throughout the time course as well. At the 24-hour time point, a few helper T cells had observable 
glycogen granulation despite the evidence of activation. After 48-hours, the proportion of helper 
T cells containing substantial granulation appeared to increase from 24-hour activated helper T 
cells. The non-activated control was used as a baseline because there were no PAS-granules. The 
stain became concentrated in the granules instead of being diffused throughout the cytoplasm. 
Glycogen granules appeared larger, more resolved and abundant at 48-hours. The significant 
increase in PAS-glycogen signal intensity validates the aforementioned observation. Previously, 
Tabatabaei Shafiei observed, in activated PBMCs, that the smaller cells (which were most likely 
lymphocytes, defined by a diameter of < 5𝜇m), were almost all positive for glycogen. Using 
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isolated helper T cells, there was an observable proportion of overall glycogen positive cells than 
was seen in PBMCs. This supported previous findings that glycogen granules are primarily found 
in T lymphocytes within PBMC suspensions. Furthermore, of the observed stained helper T cells, 
some cells contained glycogen granulation. Therefore, the question still remained; which are the 
cells that contain glycogen? 
Not all activated helper T cells visibly contained glycogen granules in vitro. Since a 
heterogenous population of helper T cells was activated in vitro, the next step would be to 
determine which cell type accumulated glycogen in the initial stages of activation. This thesis 
presents novel evidence that glycogen accumulation peaks at 48-hours post activation with anti-
CD3/anti-CD28 in both PBMCs and isolated helper T cells. In most cases, a naïve helper T cell 
response in vivo peaks between 7-15 days after being exposed to its cognate antigen (Pennock et 
al., 2013). Memory helper T cells are primed and significantly quicker at responding to stimulus 
(proliferating and producing cytokines) than naïve helper T cells. In the blood of our participants, 
and therefore in the isolated helper T cells used for our experimentation, a small percentage of 
cells were most likely effector memory helper T cells or other already differentiated helper T cell 
subsets (Th1, Th2, Th17, etc.). Future directions would involve sorting the helper T cells into 
subsets to better understand how glycogen dynamics vary between differentiated helper T cells. 
Single-cell RNAseq could be used in tandem to analyze RNA expression of glycogen pathway 
genes in differentiated helper T cells. 
 
5.3 Glycogenolysis inhibition and T lymphocyte proliferation 
 Inhibition of glycogenolysis in PBMCs resulted in the reduction of proliferation and pro-
inflammatory cytokine production. I showed that inhibition of glycogen breakdown in activated T 
lymphocytes caused a greater accumulation of glycogen than PBMCs activated alone. 
Additionally, treatment with GPI resulted in a significant decrease in proliferation for PBMCs in 
vitro. GPI has limitations because it can have off-target effects on the T lymphocytes that could be 
influencing their effector function. Although the concentration of inhibitor used was in accordance 
with the manufacturer’s instructions it would be useful, in the future, to assess the proper GPI 
concentration using a dose response.  
Glycogen dynamics varied depending on the serum levels. Glycogen signal intensity was 
lower for PBMCs cultured in 1% serum than those cultured in 10% serum. This reflected the 
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findings from Tabatabaei Shafiei 2016, where she found, using a serum titration experiment, that 
glycogen availability in PBMCs was dependent on there being higher serum levels during 
activation with anti-CD3/anti-CD28 in vitro. In culture, glucose availability is primarily dependent 
on the amount of serum (FBS was used in this thesis) added to media preparations. It is possible 
that, in a low glucose environment (simulated using media with 1% serum), activated PBMCs 
quickly depleted glycogen to ensure they could continue to proliferate. Therefore, glycogen could 
be used to ensure the cell has a sufficient supply of glucose to continue carrying out its effector 
functions. 
 
5.4 Glycogen pathway mRNA expression in activated helper T cells 
In activated helper T cells, there was a difference in the expression of genes involved in 
glycogen pathways. Two publicly available GEO data sets were analyzed individually to make 
inferences about the RNA expression. The authors published data using two different formulas to 
obtain their data; TPM and RPKM (Appendix 1, formula 2 and 3). In both cases, the transcript 
profile changed for important glycogen related genes in response to 48-hours of activation with 
dynabeads. In helper T cells, there was a change in expression for genes involved in both 
glycogenesis and glycogenolysis due to activated. Helper T cells could favor the breakdown or 
synthesis of glycogen depending on the need at the time in the cell cycle. Glycogen could be 
degraded to provide biosynthetic substrate in preparation for G1/S phase. Alternatively, the cell 
could favor glycogen accumulation when the cell does not require as many by-products derived 
from glycolysis. While this RNAseq data provides insight into the change in expression for genes 
involved in glycogen dynamics, there could also be changes at the protein level. Post-translational 
modifications of proteins could be responsible for changes in the glycogen dynamics profile, of 
the helper T cells, to favour either glycogenesis or glycogenolysis. This RNAseq data could be 
coupled with future protein analysis such as mass spectroscopy followed by enzyme assays to 
determine the changes in activity of certain enzymes involved. This data provided evidence that in 
helper T cells glycogen can be broken down at the same time as it can be rebuilt, and cements the 




5.5 Role of glycogen in helper T cells 
There has been limited work done on glycogen dynamics in helper T cells. It was important 
to obtain information from other cell types to make valid speculations, because of the lack of prior 
literature on glycogen dynamics in helper T cells. In this thesis, I used astrocytes as a control to 
optimize and establish 2-NBDG, in order to eventually observe glycogen in lymphocytes. The 
literature on glycogen dynamics in astrocytes is useful in order to draw inferences on how glycogen 
dynamics occurs in helper T cells. One job of an astrocyte is to metabolize glycogen into lactate 
and then shuttle it to neurons. Similarly, helper T cells provide a support role in immunity. Like 
astrocytes, activated helper T cells produce an increased amount of lactate in an inflammatory 
environment (Grist et al., 2018). Lactate production, from helper T cells, could be used to 
modulate the activity of other immune cells in the inflammatory microenvironment. Immune cell 
modulation, due to lactate, has been studied in a tumor microenvironment where cytotoxic T cells 
take up lactate, leading to their inhibition (Fischer et al., 2007). Glycogen accumulation in helper 
T cells could be a way for them to provide signalling to other immune cells in response to a 
stimulus. There are possibly other physiological functions to glycogen in activated helper T cells. 
Glycogen could be important for regulating osmotic pressure when the helper T cell 
proliferates. Activated helper T cells need to acquire glucose during an immune response. The 
increase in soluble glucose disrupts the osmotic pressure of the cell. Glycogen does not cause an 
osmotic imbalance for the cell, and therefore, could be a method for them to effectively store 
surplus glucose. Glycogen accumulation may allow the helper T cell to modulate the function of 
other immune cells while ensuring they do not encounter a disproportion of osmotic pressure. 
 
5.6 Future directions 
One direction of this project could be to improve upon the techniques for glycogen 
visualization, in order to better track the dynamics of glycogen in helper T cells. The current 
limitation of PAS-glycogen signal intensity measurements is that small changes in concentration 
are difficult to record. Expansion of glycogen visualization techniques with 2-NBDG would allow 
for higher resolution images of glycogen and therefore a better representation of small changes in 
glycogen concentration. Additionally, 2-NBDG could provide an optimal tool for visualizing 
glycogen dynamics in real time. 2-NBDG also would be a useful technique to explore earlier time 
points of activation. I explored glycogen dynamics at 30-minutes, 24, 48 and 72-hours after 
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activation. There is a possibility that glycogen is most active at earlier time points, which 2-NBDG 
visualization at earlier time points could address. In the case of helper T cells 2-NBDG can be 
coupled with fluorescent antibodies to identify specific subsets of helper T cells. For example, 
using 2-NBDG with fluorescent antibodies for CD4, CD3 and intracellular FoxP3 would allow 
monitoring of glycogen dynamics in the Treg subset. In addition to 2-NBDG optimization, it would 
also be useful to obtain a more expansive RNA expression profile for helper T cells, by using 
single-cell RNA sequencing. With this sequencing data, scientists could more precisely pinpoint 
which branching glycolytic pathways are required for helper T cell to proliferate and undergo 
clonal expansion. These proposed experiments would provide more evidence that glycogen is 
accumulating in helper T cells. 
Future directions should address the functionality of glycogen in the helper T cell. Further 
analysis using inhibitors for the glycogen pathway (for both glycogenesis and glycogenolysis) 
would be useful in establishing the role of glycogen in activated helper T cells. Here, it was shown 
that GPI had a negative effect on the proliferation of helper T cells in vitro. It would be useful to 
find other gene targets that could either be knocked out or inhibited without affecting other 
important processes within the cell. Adoptive transfer of helper T cells post immunoablation, in a 
diseased/infection animal model (mice for example) would provide a newfound understanding of 
how glycogen dynamics in helper T cells affects the immune systems’ ability to fight infection or 
disease in vivo. 
 
5.7 Studying glycogen metabolism in helper T cells to understand health and disease 
In the 1960s, there were reports that the activation of PBMCs caused glycogen 
accumulation. The changes in glycogen concentration was being explored as a diagnostic tool for 
cancers. In patients with chronic or acute lymphocytic leukemia, lymphocytes had increased 
glycogen levels (Bennett and Dutcher, 1969). The Quaglino and Hedeskov group attempted to use 
PAS staining to create a link between increases in glycogen content in lymphocytes and cancer 
diagnosis (Hayhoe and Quaglino, 1965; Hedeskov, 1968). Controversial findings contributed to 
the abandonment of PAS staining as a diagnostic tool for cancer (Jones et al., 1962; Leder and 
Donhuijsen, 1978). PAS-positivity was an indication of prognosis only for cancers effecting 
lymphocytes directly, such as lymphoblastic leukemia and Hodgkin’s disease. Even though PAS 
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staining was not a good diagnosis for all cancers, PAS-glycogen staining in lymphocytes was 
integrated into the diagnosis of a lysosomal disorder called Pompe’s disease.  
In the lymphocytes of patients with glycogen storage disease (GSD), such as Pompe’s 
disease, their lysosomes fail to degrade glycogen and accumulate autophagic vacuoles that stain 
purple with PAS (Hagemans et al., 2010; Pascarella et al., 2018). PAS test can be done on blood 
smears, making it a fast and easy test. For GSD, enzyme replacement therapy is most common. 
Specifically, mutations in acid alpha-glucosidase gene (GAA) are responsible for the enzymes 
inability to cleave glycosidic bonds of glycogen in lysosomes. Since its introduction in 2006, 
restoration of glycogen dynamics through gene therapy has reduced instances of mortality and 
morbidity of GSD (Pascarella et al., 2018). This highlights a prime example of glycogen dynamics 
in lymphocytes playing an important role in health and disease.  
 
5.8 Conclusion 
To summarize, I provided evidence of glycogen accumulation in helper T cells. Based on 
the results, there is reason to believe that glycogen dynamics play a role in the effector function of 
helper T cells. This is amongst the first accounts of glycogen dynamics in helper T cells. Helper T 
cells are one of the most important cells of the immune system. The presence of glycogen dynamics 
in helper T cells and its involvement in proliferation could reveal its usefulness as a target for 
therapy with future experimentation. There is still a lot to be learned about helper T cells and their 
metabolism. It is important to continually uncover new pathways that affect their function. The 
more knowledge that becomes available on healthy immune cells, the better chance there is to 
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% 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 − 𝐷𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
) × 100 
 
 
Formula 1 – Calculation for % viability through trypan counting.  
As explained in the methods section, trypan solution was added in a 1:1 ratio with live cells. Cells that have died will 
take up the trypan solution and will appear blue and opaque. The number of dead cells was subtracted from the total 







Formula 2 – RPKM calculation.  
For reporting results as RPKM, calculations attempt to normalize for sequencing depth and gene length. The first step 
is to normalize for the number of reads per gene (C). Then, divide the total number of reads for the gene (in kilobases) 













 × 106 
Formula 3 – TPM calculation.  
TPM represents the relative number of RNA transcript (i) for every million RNA molecules in the experiment sample. 
This formula was carried out per gene. First the transcript expression value was normalized by counting the number 
of reads for a gene (Ci) and then, for that gene (i), the number of reads (C) was divided by the length of gene transcript 
(Li). This output (Ci/Li) was multiplied by the inverse of the sum for all counts per base of all genes (Cj/Lj) then all 








Supplemental Figure 1 – Fiji macro for cell area and signal intensity 
The images contrast was enhanced, and the green channel was split out. The green channel has the most contrast and 
is why this channel was chosen. Next, the image was blurred to hide small artifacts such as cell debris. Lastly the 
macro told Fiji to threshold the image to find areas above 1500 pixels in size which we assumed were cells. Lastly, 








Supplemental Figure 2 – PAS Staining patterns between time points for helper T cells 
This figure depicts the pattern of PAS staining between 24- and 48-hour time points. Helper T cells that were stained 
at 24-hours after activation were consistently darker purple with diffuse staining throughout the inside of the cell 







Supplemental Figure 3 – 2-NBDG in PBMCs 
Immunofluorescent images of PBMCs show 2-NBDG (green) did not effectively form granules inside PBMCs. 
PBMCs seem to be auto-fluorescent and therefore 2-NBDG is an unreliable method for measuring glycogen. 2-NBDG 
signal (green) is observed in control conditions (no 2-NBDG). DAPI (blue) was used as a nuclear stain. Magnification 
= 60x 
 
